CVS HEALTH Corp (CVS) stock

CVSNYSERetail-Drug Stores and Proprietary StoresFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/3016% above fair value

$90.25−0.08 (-0.09%)

Close on Oct 30, 2026Market cap $115.43BP/E 23.9Yield 2.95%

Earnings

Cvs Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Oct 28, 2026

Q3 FY2026 · estimated, before the open

Revenue, Q2 FY2026

$106.10B

+7.3% on a year earlier

Adjusted EPS, Q2 FY2026

$2.58

$1.81 a year earlier

Latest guidance

Raised

Aug 5, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Cvs Health's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 30, 2026	Oct 28, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 30, 2026	Aug 5, 2026before the open	$106.10B	+7.3%	$2.31	$2.58	Release
Q1 FY2026ended Mar 31, 2026	May 6, 2026before the open	$100.40B	+6.1%	$2.30	$2.57	Release
Q4 FY2025ended Dec 31, 2025	Feb 10, 2026before the open	$105.70B	+8.2%	$2.30	$1.09	Release
Q3 FY2025ended Sep 30, 2025	Oct 29, 2025before the open	–	–	–	$1.60	Release
Q2 FY2025ended Jun 30, 2025	Jul 31, 2025before the open	$98.90B	+8.4%	$0.80	$1.81	Release
Q1 FY2025ended Mar 31, 2025	May 1, 2025before the open	$94.60B	+7.0%	$1.41	$2.25	Release
Q4 FY2024ended Dec 31, 2024	Feb 12, 2025before the open	$97.70B	+4.2%	$1.30	$1.19	Release
Q3 FY2024ended Sep 30, 2024	Nov 6, 2024before the open	$95.40B	+6.2%	$0.07	$1.09	Release
Q2 FY2024ended Jun 30, 2024	Aug 7, 2024before the open	$91.20B	+2.6%	$1.41	$1.83	Release
Q1 FY2024ended Mar 31, 2024	May 1, 2024before the open	$88.40B	+3.6%	$0.88	$1.31	Release
Q4 FY2023ended Dec 31, 2023	Feb 7, 2024before the open	$93.80B	+11.9%	$1.58	$2.12	Release
Q3 FY2023ended Sep 30, 2023	Nov 1, 2023before the open	$89.80B	+10.6%	$1.75	$2.21	Release
Q2 FY2023ended Jun 30, 2023	Aug 2, 2023before the open	$88.90B	+10.3%	$1.48	$2.21	Release
Q1 FY2023ended Mar 31, 2023	May 3, 2023before the open	$85.30B	+11.1%	$1.65	$2.20	Release
Q4 FY2022ended Dec 31, 2022	Feb 8, 2023before the open	$83.80B	+9.4%	$1.75	$1.99	Release
Q3 FY2022ended Sep 30, 2022	Nov 2, 2022before the open	$81.20B	+10.0%	-$2.60	$2.09	Release
Q2 FY2022ended Jun 30, 2022	Aug 3, 2022before the open	$80.60B	–	$2.23	$2.40	Release
Q1 FY2022ended Mar 31, 2022	May 4, 2022before the open	$76.80B	–	$1.74	$2.22	Release
Q4 FY2021ended Dec 31, 2021	Feb 9, 2022before the open	$76.60B	–	$0.98	$1.98	Release
Q3 FY2021ended Sep 30, 2021	Nov 3, 2021before the open	$73.80B	–	$1.20	$1.97	Release
Q2 FY2021ended Jun 30, 2021	Aug 4, 2021before the open	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 4, 2021before the open	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 16, 2021before the open	–	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Nov 6, 2020before the open	–	–	–	–	Filing
Q2 FY2020ended Jun 30, 2020	Aug 5, 2020before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Cvs Health's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Total revenues	FY2026	$414.00B	$405.00B	Raised	Aug 5, 2026
GAAP diluted EPSGAAP	FY2026	$6.84 – $7.04	$6.24 – $6.44	Raised	Aug 5, 2026
Adjusted EPSnon-GAAP	FY2026	$7.90 – $8.10	$7.30 – $7.50	Raised	Aug 5, 2026
Cash flow from operations	FY2026	$11.50B	$9.50B	Raised	Aug 5, 2026

Guidance vs results

The last range Cvs Health gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Adjusted EPS	$6.55 – $6.65	$6.75Σ4Q	Above range
Q3 FY2024	Adjusted EPS	$1.05 – $1.10	$1.09	Within range
Q3 FY2024	EPS (GAAP)	$0.03 – $0.08	$0.07	Within range

Guidance history

Every forecast Cvs Health put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Aug 5, 2026	Adjusted EPS	FY2026	$7.90 – $8.10	Raised
Aug 5, 2026	GAAP diluted EPS	FY2026	$6.84 – $7.04	Raised
Aug 5, 2026	Cash flow from operations	FY2026	$11.50B	Raised
Aug 5, 2026	Total revenues	FY2026	$414.00B	Raised
May 6, 2026	Adjusted EPS	FY2026	$7.30 – $7.50	Raised
May 6, 2026	GAAP diluted EPS	FY2026	$6.24 – $6.44	Raised
May 6, 2026	Cash flow from operations	FY2026	$9.50B	Raised
May 6, 2026	Total revenues	FY2026	$405.00B	New
Feb 10, 2026	Adjusted EPS	FY2026	$7.00 – $7.20	New
Feb 10, 2026	GAAP diluted EPS	FY2026	$5.94 – $6.14	New
Feb 10, 2026	cash flow from operations	FY2026	$9.00B	New
Oct 29, 2025	Adjusted EPS	FY2025	$6.55 – $6.65	Raised
Oct 29, 2025	GAAP diluted earnings (loss) per share	FY2025	-$0.34 – -$0.24	Lowered
Oct 29, 2025	cash flow from operations	FY2025	$7.50B – $8.00B	Raised
Jul 31, 2025	Adjusted EPS	FY2025	$6.30 – $6.40	New
Jul 31, 2025	GAAP diluted EPS	FY2025	$3.84 – $3.94	New
Jul 31, 2025	cash flow from operations	FY2025	$7.50B	New
May 1, 2025	Adjusted EPS	FY2025	$6.00 – $6.20	Raised
May 1, 2025	GAAP diluted EPS	FY2025	$4.23 – $4.43	Lowered
May 1, 2025	cash flow from operations	FY2025	$7.00B	Raised
Feb 12, 2025	Adjusted EPS	FY2025	$5.75 – $6.00	New
Feb 12, 2025	GAAP diluted EPS	FY2025	$4.58 – $4.83	New
Feb 12, 2025	cash flow from operations	FY2025	$6.50B	New
Oct 18, 2024	Adjusted EPS	Q3 FY2024	$1.05 – $1.10	New
Oct 18, 2024	GAAP diluted EPS	Q3 FY2024	$0.03 – $0.08	New
Oct 18, 2024	Medical Benefit Ratio (“MBR”)	Q3 FY2024	95.2%	New
Aug 7, 2024	Adjusted EPS	FY2024	$6.40 – $6.65	Lowered
Aug 7, 2024	GAAP diluted EPS	FY2024	$4.95 – $5.20	Lowered
Aug 7, 2024	cash flow from operations	FY2024	$9.00B	New
May 1, 2024	Adjusted EPS	FY2024	$7.00	Lowered
May 1, 2024	GAAP diluted EPS	FY2024	$5.64	Lowered
May 1, 2024	cash flow from operations	FY2024	$10.50B	Lowered
Feb 7, 2024	Adjusted EPS	FY2024	$8.30	New
Feb 7, 2024	GAAP diluted EPS	FY2024	$7.06	New
Feb 7, 2024	cash flow from operations	FY2024	$12.00B	New
Nov 1, 2023	Adjusted EPS	FY2023	$8.50 – $8.70	Reaffirmed
Nov 1, 2023	GAAP diluted EPS	FY2023	$6.37 – $6.61	Lowered
Nov 1, 2023	cash flow from operations	FY2023	$12.50B – $13.50B	Reaffirmed
Aug 2, 2023	Adjusted EPS	FY2023	$8.50 – $8.70	Reaffirmed
Aug 2, 2023	GAAP diluted EPS	FY2023	$6.53 – $6.75	Lowered
Aug 2, 2023	cash flow from operations	FY2023	$12.50B – $13.50B	Reaffirmed
May 3, 2023	Adjusted EPS	FY2023	$8.50 – $8.70	Lowered
May 3, 2023	GAAP diluted EPS	FY2023	$6.90 – $7.12	Lowered
May 3, 2023	cash flow from operations	FY2023	$12.50B – $13.50B	Reaffirmed
Feb 8, 2023	Adjusted EPS	FY2023	$8.70 – $8.90	New
Feb 8, 2023	GAAP diluted EPS	FY2023	$7.73 – $7.93	New
Feb 8, 2023	cash flow from operations	FY2023	$12.50B – $13.50B	New
Nov 2, 2022	Adjusted EPS	FY2022	$8.55 – $8.65	Raised
Nov 2, 2022	GAAP diluted EPS	FY2022	$3.12 – $3.22	Lowered
Nov 2, 2022	cash flow from operations	FY2022	$13.50B – $14.50B	Raised
Aug 3, 2022	Adjusted EPS	FY2022	$8.40 – $8.60	Raised
Aug 3, 2022	GAAP diluted EPS	FY2022	$7.23 – $7.43	Raised
Aug 3, 2022	cash flow from operations	FY2022	$12.50B – $13.50B	Raised
May 4, 2022	Adjusted EPS	FY2022	$8.20 – $8.40	Raised
May 4, 2022	GAAP diluted EPS	FY2022	$6.93 – $7.13	Lowered
May 4, 2022	cash flow from operations	FY2022	$12.00B – $13.00B	New
Feb 9, 2022	Adjusted EPS	FY2022	$8.10 – $8.30	New
Feb 9, 2022	GAAP diluted EPS from continuing operations	FY2022	$7.04 – $7.24	New
Feb 9, 2022	cash flow from operations	FY2022	$12.00B – $13.00B	New
Nov 3, 2021	Adjusted EPS	FY2021	$7.90 – $8.00	New
Nov 3, 2021	GAAP diluted EPS	FY2021	$6.13 – $6.23	New
Nov 3, 2021	cash flow from operations	FY2021	$13.00B – $13.50B	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.